Clinical Trial Update: ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating ADP101 for oral immunotherapy in children and adults with food allergy has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Food Allergy

Drugs mentioned

• ADP101

Snippet

Sponsor: Alladapt Immunotherapeutics, Inc. | Conditions: Food Allergy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-05-16